https://mergers.whitecase.com/highlights/oncology-dealmaking-fuels-biotech-ma#!
Global spending on cancer medicines is set to reach US$375 billion by 2027, with innovation in drug discovery and development ramping up to meet rising demand.Outlook
Looking ahead, innovation in oncology looks set to ramp up even further. Exponential growth in demand will provide a steady stream of new assets coming to market, presenting prime deal opportunities for pharmaceutical companies and private investors alike.
The industry’s drive to snap up oncology targets shows no sign of slowing down. Oncology drugs are among the most profitable in the market, and pharma companies will be looking to replenish lost revenue streams in anticipation of impending patent expirations.
With these strong market tailwinds, dealmaking targeting oncology assets will be an exciting space to watch.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.5¢ | 0.4¢ | $11.72K | 2.783M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 2757364 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 15260220 | 25 |
View Market Depth
| Last trade - 16.10pm 23/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |